SIV/Macaque Model of HIV Infection in Cocaine Users: Minimal Effects of Cocaine on Behavior, Virus Replication, and CNS Inflammation
- 211 Downloads
Studies of the effects of drugs of abuse on HIV immune status, disease progression, and neuroAIDS have produced conflicting data and have not definitively shown whether this combination promotes cognitive impairment or disease progression. Using a consistent SIV–macaque model, we investigated the effects of cocaine on behavior, virologic parameters, and CNS inflammation. Macaques received either vehicle or chronic administration of behaviorally active doses of cocaine (1.7 or 3.2 mg/kg/day). Chronic cocaine administration reduced CD8+ T cell counts during acute and late stage infection but had no effect on CD4+ T cell counts. Low-dose cocaine-treated animals had lower CSF vRNA levels late in infection, but cocaine did not alter plasma viral load or vRNA or protein in brain. There were no differences in CSF CCL-2 or interleukin (IL)-6 levels or severity of encephalitis in cocaine-treated as compared to vehicle-treated macaques. There were no differences in brain inflammation or neurodegeneration markers, as determined by interferon (IFN)-β, MxA, CCL2, IL-6, TNFα, IFNγ, and indolamine 2,3-deoxygenase mRNA levels. APP levels also were not altered. The executive function of inhibitory control was not impaired in cocaine-treated or control animals following SIV infection. However, animals receiving 3.2 mg/kg/day cocaine performed more slowly in a bimanual motor test. Thus, chronic administration of cocaine produced only minor changes in behavior, encephalitis severity, CNS inflammation/neurodegeneration, and virus replication in SIV-infected pigtailed macaques, suggesting that cocaine would have only modest effects on the progression of neuroAIDS in HIV-infected individuals.
KeywordsSIV HIV Cocaine Macaque Behavior CD4 NeuroAIDS
MW and MCZ funded this study.
The authors have no conflict of interests to disclose.
Sources of funding
This study was funded by NIH R01 DA12829, DA05831, and a gift from the Susan R. Scherer Educational Foundation.
- Centers for Disease Control and Prevention (2002) Fact sheet: drug-associated HIV transmission continues in the United States. Department of Health and Human Services, Centers for Disease Control and Prevention, AtlantaGoogle Scholar
- Concha M, Graham NM, Munoz A, Vlahov D, Royal W 3rd, Updike M, Nance-Sproson T, Selnes OA, McArthur JC (1992) Effect of chronic substance abuse on the neuropsychological performance of intravenous drug users with a high prevalence of HIV-1 seropositivity. Am J Epidemiol 136:1338–1348PubMedGoogle Scholar
- Hughes A, Sathe N, Spagnola K (2008) State estimates of substance use from the 2005–2006 national surveys on drug abuse and health. Dept. of Health and Human Services, Substance Abuse and Mental Health Services Administration, Office of Applied Studies, RockvilleGoogle Scholar
- Rodriguez-Arenas MA, Jarrin I, del Amo J, Iribarren JA, Moreno S, Viciana P, Pena A, Sirvent JL, Vidal F, Lacruz J, Gutierrez F, Oteo JA, Asencio R, Castilla J, Hoyos SP (2006) Delay in the initiation of HAART, poorer virological response, and higher mortality among HIV-infected injecting drug users in Spain. AIDS Res Hum Retroviruses 22:715–723PubMedCrossRefGoogle Scholar